Why it matters

There are no comprehensive, generally agreed and universally applicable guiding principles and criteria governing rigour in the design, conduct and analysis of pre-clinical neuroscience and safety research, although there is emerging consensus for the standards of reporting such research.

As a result, the development of new medicines has slowed dramatically in the last 10 years, with the number of drugs in development down by 70% since 2005. This is mostly due to the complexity of drug development leading to a significant failure rate.

The EQIPD project aims to reverse this trend.

Our consortium that unites more than 20 research groups from industry and academia will develop strategies to ensure that early drug development research proceeds along structured lines.